差别

这里会显示出您选择的修订版和当前版本之间的差别。

--- clinicaltrial [2021/04/13 06:59]
admin
+++ clinicaltrial [2021/04/16 13:18] (当前版本)
admin
@@ 行 8: / 行 8: @@
 Study List:
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 1:
  NCT Number:          NCT04671459
  Title:            TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine
  Acronym:           TaRRGET
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma Multiforme|Recurrent Glioblastoma
  Interventions:        Combination Product: TTFields and SRS
  Outcome Measures:       1-year survival rate|Radiation necrosis range|Progression free survival (PFS)|Steroid needs until treatment failure|Patterns of failure|Objective response rates
  Sponsor/Collaborators:    Prof. Franciszek Lukaszczyk Memorial Oncology Center|NovoCure GmbH
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 2
  Enrollment:          40
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          KB 2020
  Start Date:          December 26, 2020
  Primary Completion Date:   December 9, 2022
  Completion Date:       December 9, 2023
  First Posted:         December 17, 2020
  Results First Posted:
  Last Update Posted:      January 26, 2021
  Locations:          The Franciszek Lukaszczyk Oncology Center, Bydgoszcz, Poland
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT04671459
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 2:
  NCT Number:          NCT03258021
  Title:            TTFields In GErmany in Routine Clinical Care
  Acronym:           TIGER
  Status:            Active, not recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma
  Interventions:        Device: TTFields
  Outcome Measures:       Time to death of any cause (overall survival (OS)) from diagnosis|Number of TTFields treatment-related serious adverse events (SAEs) standardized to one year of FU time|Number of SAEs after start of TTFields treatment|Time of usage (compliance) of TTFields treatment over time|Time to first progression of GBM (progression-free survival (PFS)), defined within radiological and/or clinical/neurological assessment during routine clinical care in patients who started TTFields treatment at baseline|Changes in quality of life at month 2 and month 4 after start of TTFields treatment compared to baseline in patients who started TTFields treatment at baseline|Patients' reason(s) for refusing TTFields at baseline
  Sponsor/Collaborators:    NovoCure Ltd.
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:
  Enrollment:          710
  Funded Bys:          Industry
  Study Type:          Observational
  Study Designs:        Observational Model: Other|Time Perspective: Prospective
  Other IDs:          05.07.2017
  Start Date:          August 31, 2017
  Primary Completion Date:   June 2021
  Completion Date:       July 2021
  First Posted:         August 22, 2017
  Results First Posted:
  Last Update Posted:      January 28, 2021
  Locations:          Clinical center Aschaffenburg-Alzenau, Aschaffenburg, Bavaria, Germany
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03258021
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 3:
  NCT Number:          NCT04717739
  Title:            TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study
  Acronym:
  Status:            Not yet recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma
  Interventions:        Device: TTFields
  Outcome Measures:       Time of usage of TTFields treatment in follow-up derived from monitoring data of the devices, standardised to usage days, as measure of compliance with TTFields treatment.|Number of TTFields treatment-related SAEs as assessed by the CEC standardized to one year of FU time|Changes in daily physical activity as a potential quality of life parameter in TTFields treatment compared to baseline for up to four months after start of TTFields therapy|Changes in sleep quality as a potential quality of life parameter in TTFields treatment compared to baseline for up to four months after start of TTFields therapy|Changes in neurocognitive functioning as a potential quality of life parameter in TTFields treatment compared to baseline for up to four months after start of TTFields therapy.
  Sponsor/Collaborators:    NovoCure Ltd.
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:
  Enrollment:          500
  Funded Bys:          Industry
  Study Type:          Observational
  Study Designs:        Observational Model: Other|Time Perspective: Prospective
  Other IDs:          13.01.2021
  Start Date:          March 2021
  Primary Completion Date:   June 1, 2023
  Completion Date:       July 1, 2023
  First Posted:         January 22, 2021
  Results First Posted:
  Last Update Posted:      January 22, 2021
  Locations:          University Hospital Essen, Essen, Germany
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT04717739
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 4:
  NCT Number:          NCT02973789
  Title:            Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Nonsmall Cell Lung Cancer
  Interventions:        Device: NovoTTF-100L|Drug: Immune checkpoint inhibitors or docetaxel
  Outcome Measures:       Overall survival of patients treated with TTFields + docetaxel or immune checkpoint inhibitors vs. docetaxel or immune checkpoint inhibitors alone (superiority analysis)|Overall survival of patients treated with TTFields + docetaxel vs. docetaxel alone (superiority analysis)|Overall survival of patients treated with TTFields + immune checkpoint inhibitors vs. immune checkpoint inhibitors alone (superiority)|Overall Survival of patients treated with TTFields + docetaxel Vs. immune checkpoint inhibitors alone (non-inferiority analysis)|Progression-free survival of patients treated with docetaxel or immune checkpoint inhibitors + TTFields vs. docetaxel or immune checkpoint inhibitors alone, based on RECIST Criteria|Overall radiological response rate (based on RECIST criteria) of patients treated with docetaxel or Immune checkpoint inhibitors + TTFields vs. docetaxel or immune checkpoint inhibitors alone.|Quality of life using the EORTC QLQ C30 questionnaire with LC13 addendum|Analyses of the effects of NovoTTF-100L with each type of immune checkpoint inhibitor on overall survival and progression free survival|Analysis of the effects of NovoTTF-100L on overall survival and progression free survival within each histological subgroup (squamous and non-squamous)|The effect of treatment compliance with NovoTTF-100L on overall survival and progression free survival outcomes|Adverse events, severity and frequency based on Common Terminology Criteria for Adverse Events (CTCAE) V4.03
  Sponsor/Collaborators:    NovoCure Ltd.
  Gender:            All
  Age:             22 Years and older   (Adult, Older Adult)
  Phases:            Phase 3
  Enrollment:          534
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          EF-24
  Start Date:          December 2016
  Primary Completion Date:   September 2023
  Completion Date:       September 2023
  First Posted:         November 25, 2016
  Results First Posted:
  Last Update Posted:      March 24, 2021
  Locations:          Central Alabama Research, Birmingham, Alabama, United States|Ironwood Cancer & Research Center, Chandler, Arizona, United States|Cancer Center at St. Joseph Hospital and Medical Center, Phoenix, Arizona, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|California Cancer Associates for Research and Excellence, Inc. cCARE, Fresno, California, United States|Saddleback Memorial Medical Center, Laguna Hills, California, United States|Dignity Health - Mercy Cancer Centers, Sacramento, California, United States|Sutter Institute for Medical Research, Sacramento, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Banner MD Anderson Cancer Center at North Colorado Medical Center, Greeley, Colorado, United States|Associated Neurologists of Southern CT, P.C., Fairfield, Connecticut, United States|Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Adult Oncology Research, Orlando, Florida, United States|BRCR Medical Center INC, Plantation, Florida, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Illinois CancerCare, P.C., Peoria, Illinois, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|University Medical Center, Inc; DBA University of Louisville, Louisville, Kentucky, United States|Tulane Cancer Center, New Orleans, Louisiana, United States|CHRISTUS Health, Shreveport, Louisiana, United States|Central Maine Medical Center, Lewiston, Maine, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Tufts Medical Center, Division of Hematology and Oncology, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Clinical Oncology Associates, Farmington Hills, Michigan, United States|Detroit Clinical Research Center, Farmington Hills, Michigan, United States|Saint Joseph Mercy Health System, Ypsilanti, Michigan, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CHI Health Research Center, Omaha, Nebraska, United States|Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Renown Regional Medical Center Institute for Cancer, Reno, Nevada, United States|Presbyterian Cancer Center, Albuquerque, New Mexico, United States|New York-Presbyterian/Queens Radiation Oncology, Flushing, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Stony Brook Cancer Center, Stony Brook, New York, United States|Oncology Specialists of Charlotte, Charlotte, North Carolina, United States|W.G. Bill Hefner VA Med Center, Salisbury, North Carolina, United States|Piedmont Radiation Oncology, PA, Winston-Salem, North Carolina, United States|Summa Health, Akron, Ohio, United States|Toledo Clinic Cancer Center, Toledo, Ohio, United States|Vita Medical Associates, P.C., Bethlehem, Pennsylvania, United States|Geisinger Cancer Institute, Danville, Pennsylvania, United States|UT/Erlanger Oncology & Hematology, Chattanooga, Tennessee, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology - Arlington, Arlington, Texas, United States|Christus Health Spohn Ministry, Corpus Christi, Texas, United States|Dallas VA Medical Center, Dallas, Texas, United States|Texas Oncology- Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States|Oncology Consultants, P.A., Houston, Texas, United States|Texas Oncology-McKinney, McKinney, Texas, United States|Texas Oncology - Paris, Paris, Texas, United States|Texas Oncology- Plano West, Plano, Texas, United States|Baylor Scott & White Health/McClinton Cancer Center, Waco, Texas, United States|Texas Oncology-Waco, Waco, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Overlake Medical Center & Clinics, Bellevue, Washington, United States|UW Carbone Cancer Center, Madison, Wisconsin, United States|Uniklinikum Salzburg Landeskrankenhaus - Universitätsklinik für Innere Medizin III der PMU, Salzburg, Austria|Institut Jules Bordet - Department of Intensive Care and Thoracic Oncology, Brussels, Belgium|André Renard Clinic, Herstal, Belgium|AZ Sint Maarten, Mechelen, Belgium|McGill University Health Centre, Montréal, Quebec, Canada|Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, Quebec, Canada|Allan Blair Cancer Center, Regina, Saskatchewan, Canada|Thomayerova Nemocnice Dept. of Pneumology, Prague, Czechia|Všeobecná Fakultní Nemocnice, Prague, Czechia|Vitkovicka nemocnice, Vitkovice, Czechia|Centre Hospitalier de Beauvais, Beauvais, France|INSTITUT BERGONIE Centre Régional de Lutte Contre le Cancer, Bordeaux, France|Hospital Centre of Brittany SUDF (CHBS), Lorient, France|CHU de Nîmes ICG. - Service de pneumologie, Nîmes, France|Hôpital Saint-Louis, Paris, France|Hospital Centre of Saint-Quentin, Saint-Quentin, France|Universitätsklinikum Halle (Saale) - Klinik und Poliklinik für Innere Medizin IV Onkologie/Hämatologie, Halle (Saale), Germany|Azienda Sociosanitaria Ligure 3 (ASL 3), Genova, Italy|IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy|UOC Oncologia Medica Presidio Ospedaliero di Ravenna, Ravenna, Italy|ASST della Valle Olona - Presidio Ospedaliero di Saronno, Saronno, Italy|St Jansdal Ziekenhuis, Harderwijk, Netherlands|Erasmus Mc, Rotterdam, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|MS Clinsearch Specjalistyczny NZOZ, Lublin, Poland|Katedra i Klinika Onkologii; Szpital Kliniczny Przemienienia Pańskiego UM w Poznaniu, Poznan, Poland|Samodzielny Publiczny Wojewódzki Szpital Zespolony w Szczecinie, Oddział Onkologii Klinicznej i Chemioterapii, Szczecin, Poland|Centrum Terapii Współczesnej, Łódź, Poland|Hospital Universitario Arnau de Vilanova, Lleida, Catalonia, Spain|Hospital Quirón Teknon, Instituto Oncológico Dr. Rosell, Barcelona, Spain|HGU Gregorio Marañón, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Universitario Málaga Regional. IBIMA, Málaga, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Universitari i Politécnic La Fe, Valencia, Spain|KS Winterthur, Medizinische Onkologie, Winterthur, Switzerland
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT02973789
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 5:
  NCT Number:          NCT04492163
  Title:            Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma Multiforme
  Interventions:        Device: TTFields
  Outcome Measures:       Progression free survival (PFS)|Overall Survival (OS)|Progression Free Survival at 6 months (PFS6)|1-year and 2-year survival rates|Overall radiological response|Severity and frequency of adverse events|Pathological changes in resected GBM tumors following study treatment|Dependence of Progression Free Survival on TTFields dose delivered to the tumor bed|Dependence of Overall Survival on TTFields dose delivered to the tumor bed
  Sponsor/Collaborators:    NovoCure Ltd.
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 2
  Enrollment:          25
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          EF-33
  Start Date:          July 14, 2020
  Primary Completion Date:   January 2022
  Completion Date:       January 2022
  First Posted:         July 30, 2020
  Results First Posted:
  Last Update Posted:      November 24, 2020
  Locations:          Nemocnice Na Homolce, Prague, Czechia
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT04492163
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 6:
  NCT Number:          NCT03606590
  Title:            Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)
  Acronym:
  Status:            Active, not recruiting
  Study Results:        No Results Available
  Conditions:          Hepatocellular Carcinoma
  Interventions:        Device: NovoTTF-100L(P) device|Drug: Sorafenib
  Outcome Measures:       Overall response rate|In-field control rate at one year|Overall survival|Progression Free Survival|Distant metastases-free survival rate at 1 year|Overall survival at one year|Progression free survival at 6 and 12 months|Severity and frequency of adverse events
  Sponsor/Collaborators:    NovoCure GmbH|NovoCure Ltd.
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 2
  Enrollment:          25
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          EF-30
  Start Date:          February 15, 2019
  Primary Completion Date:   September 2021
  Completion Date:       September 2021
  First Posted:         July 31, 2018
  Results First Posted:
  Last Update Posted:      July 29, 2020
  Locations:          University Hospital Fakultni Nemocnice Olomouc, Oncology Clinic, Olomouc, Czechia|CHU de Nantes, Nantes Cedex 01, France|University Medical Center - University of Freiburg, Freiburg, Germany|Ulm University Hospital, Ulm, Germany|Università Campus Bio-Medico di Roma, Rome, Italy|Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland|Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain|HM Hospitales - Centro Integral Oncológico Clara Campal, Madrid, Spain
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03606590
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 7:
  NCT Number:          NCT03377491
  Title:            Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Pancreas Adenocarcinoma
  Interventions:        Device: NovoTTF-100L(P)|Drug: Gemcitabine|Drug: nab paclitaxel
  Outcome Measures:       Overall survival|Progression-free survival|Local progression-free survival|Objective response rate|One-year survival rate|Quality of life|Pain-free survival|Puncture-free survival|Resectability rate|Toxicity profile
  Sponsor/Collaborators:    NovoCure Ltd.
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 3
  Enrollment:          556
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          EF-27
  Start Date:          May 10, 2018
  Primary Completion Date:   September 2023
  Completion Date:       September 2023
  First Posted:         December 19, 2017
  Results First Posted:
  Last Update Posted:      March 11, 2021
  Locations:          Grandview Medical Center, Cancer Center, Birmingham, Alabama, United States|Infirmary Cancer Care, Mobile, Alabama, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Arizona Oncology Associates, PC- HOPE - US Oncology Research, Tucson, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|Pacific Cancer Medical Center, Anaheim, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Dignity Health - Mercy Cancer Centers, Sacramento, California, United States|Sutter Cancer Center Sacramento, Sacramento, California, United States|Boca Raton Regional Hospital, Lynn Cancer Institute, Boca Raton, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|AdventHealth Neuro Oncology, Orlando, Florida, United States|BRCR Medical Center INC, Plantation, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Hospital Tampa, Tampa, Florida, United States|Piedmont Cancer Institute, Atlanta, Georgia, United States|Illinois Cancer Specialist - US Oncology Research, Arlington Heights, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Medical Cancer Center, Fairway, Kansas, United States|Norton Cancer Institute, Norton Healthcare Pavilion, Louisville, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Central Maine Medical Center, Clinical Research Department, Lewiston, Maine, United States|University of Maryland Comprehensive Cancer Center, Baltimore, Maryland, United States|Maryland Oncology Hematology, P.A - US Oncology Research, Columbia, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Cancer and Hematology Centers of Western Michigan, PC, Grand Rapids, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|MidAmerica Division, Kansas City, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Kaleida Health, Buffalo, New York, United States|NYU Langone Arena Oncology, Lake Success, New York, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Willamette Valley Cancer Institute and Research Center - US Oncology Research, Eugene, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Vita Medical Associates, P.C., Fountain Hill, Pennsylvania, United States|UT/Erlanger Oncology & Hematology, Chattanooga, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|Texas Oncology - Beaumont Mamie McFaddin Ward Cancer Center - US Oncology Research, Beaumont, Texas, United States|Texas Oncology - Bedford - US Oncology Reasearch, Bedford, Texas, United States|Methodist Regional Cancer Center, Dallas, Texas, United States|Texas Oncology - Baylor - US Oncology Research, Dallas, Texas, United States|Texas Oncology - El Paso Cancer Treatment Center Gateway - US Oncology Research, El Paso, Texas, United States|Houston Methodist Cancer Center, Houston, Texas, United States|Baylor Scott and White Medical Center, Temple, Texas, United States|Texas Oncology - Tyler - US Oncology Research, Tyler, Texas, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care - US Oncology Research, Roanoke, Virginia, United States|Vista Oncology Inc PS, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|West Virginia University Cancer Institute, Morgantown, West Virginia, United States|Medical University Graz, Graz, Austria|Univ. Klinik für Innere Medizin III der PMU, Salzburg, Austria|Landes-Krankenhaus Steyr, Steyr, Austria|London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada|Centre Hospitalier de I'Universitaire de de Montreal (CHUM), Montréal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada|University Hospital Centre Zagreb, Zagreb, Croatia|Nemocnice Nový Jičín, Nový Jičín, Czechia|University Hospital Olomouc, Olomouc, Czechia|General University Hospital in Prague, Praha 2, Czechia|Nemocnice Na Bulovce, Praha 8, Czechia|Hopital haut-Léveque CHU Bordeaux - Service d'Hépato- Gastroentérologie et d'Oncologie digestive, Pessac, Bordeaux, France|Institut de Cancérologie de l'Ouest, Angers cedex, France|Centre Hospitalier de Bretagne Sud /Site du Scorff, Lorient, France|Centre Léon Bérard, Lyon, France|Service d'Oncologie médicale du Pr. Andre, Hôpital Saint-Antoine, Paris, France|Hôpital Privé des Côtes d'Armor, Plérin, France|Clinique Sainte Anne - Groupe Hospitalier Saint-Vincent, Strasbourg Oncologie Libérale, Strasbourg, France|Queen Mary Hospital, Hong Kong, Hong Kong|National Institute of Oncology, Budapest, Hungary|Bekes County Hospital, Gyula, Hungary|Bacs-Kiskun County Hospital, Kecskemét, Hungary|Tolna County Hospital, Szekszárd, Hungary|Jasz-Nagykun-Szolnok County Hospital, Szolnok, Hungary|Rambam Health Care Campus, Oncology Institute, Haifa, Israel|Sourasky Medical Center, Oncology Department, Tel Aviv, Israel|A.O. SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Università Campus Bio-Medico di Rome, Roma, Italy|A.O.U Città della Salute e della Scienza di Torino, Torino, Italy|Oncology Clinic Clinical Hospital of Przemienienia Pańskiego UM in Poznaniu, Poznań, Poland|Centrum Medyczne MrukMed, Rzeszów, Poland|Oncology and Radiotherapy Clinic, Oncology Center - Institute, Warsaw, Poland|Instituto Oncòlogico Dr. Rosell, Barcelona, Spain|Vall d´Hebron University Hospital, Barcelona, Spain|Hospital General Universitario de Elche, Elche, Spain|HM Hospitales - Centro Integral Oncologico Clara Campal - CIOCC, Madrid, Spain|Hospital Universitario Carlos Haya de Malaga, Málaga, Spain|Clinica Universiatria de Navarra, Pamplona, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Instituto Valenciano de Oncología IVO, Valencia, Spain|Hôpital Fribourgeois/Freiburger Spital, Fribourg, Switzerland|KS Winterthur, Winterthur, Switzerland
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03377491
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 8:
  NCT Number:          NCT04689087
  Title:            A Prospective, Open-label, Single-arm Clinical Study
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Recurrent Glioblastoma Multiforme
  Interventions:        Combination Product: TTFields
  Outcome Measures:       OS6|Overall survival at 12 months (OS12)|overall survival OS(refers to the time from enrollment to tumor disease death from various causes)|Progression-free survival PFS|security
  Sponsor/Collaborators:    Sun Yat-sen University
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Not Applicable
  Enrollment:          40
  Funded Bys:          Other
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:          M-TTFields
  Start Date:          April 1, 2020
  Primary Completion Date:   July 1, 2021
  Completion Date:       July 1, 2022
  First Posted:         December 30, 2020
  Results First Posted:
  Last Update Posted:      December 30, 2020
  Locations:          Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT04689087
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 9:
  NCT Number:          NCT02397928
  Title:            Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)
  Acronym:
  Status:            Completed
  Study Results:        No Results Available
  Conditions:          Malignant Pleural Mesothelioma
  Interventions:        Device: NovoTTF-100L device|Drug: Pemetrexed|Drug: Cisplatin or Carboplatin
  Outcome Measures:       Overall Survival|Progression Free Survival|Response Rate|Toxicity- incidence of adverse events
  Sponsor/Collaborators:    NovoCure Ltd.
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 2
  Enrollment:          82
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          EF-23
  Start Date:          February 2015
  Primary Completion Date:   April 2018
  Completion Date:       April 2018
  First Posted:         March 25, 2015
  Results First Posted:
  Last Update Posted:      September 25, 2018
  Locations:          Antwerp University Hospital, Thoracic Oncology, Antwerp, Belgium|Goustave Roussy - Cancer Campus Grand Paris, Villejuif, France|Universitätsklinikum Halle (Saale), Halle, Germany|A.S.O. "SS Antonio e Biagio e Cesare Arrigo", Alessandria, Italy|Cliniche Humanitas Gavazzeni, Bergamo, Italy|Ospedale Villa Scassi, Genoa, Italy|Ospedaliera di Perugia, Perugia, Italy|Ospedaliero Universitaria Pisana, Pisa, Italy|Erasmus Mc, Rotterdam, Netherlands|Medical University Gdansk, Gdansk, Poland|Katedra i Klinika Onkologii Uniwersytetu Medycznegi im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland|Klinika Nowotworów Pluca I Klatki Piersiowej, Warsaw, Poland|Vall d' Hebron Institute of Oncology (VHIO) Hospital Vall d'Hebron, Barcelona, Spain
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT02397928
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 10:
  NCT Number:          NCT03940196
  Title:            Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Ovarian Cancer
  Interventions:        Device: NovoTTF-100L(O)|Drug: Paclitaxel
  Outcome Measures:       Overall survival|Progression-free survival|Objective response rate|Next progression-free survival|Time to undisputable deterioration in health-related quality of life (HRQoL)|Time to first and second subsequent treatment|Quality of life using the EORTC QLQ C30 questionnaire with the ovarian cancer symptom OV28 module.|Severity and frequency of adverse events
  Sponsor/Collaborators:    NovoCure Ltd.
  Gender:            Female
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 3
  Enrollment:          540
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          EF-28
  Start Date:          March 22, 2019
  Primary Completion Date:   September 2023
  Completion Date:       September 2023
  First Posted:         May 7, 2019
  Results First Posted:
  Last Update Posted:      March 29, 2021
  Locations:          Arizona Oncology- Biltmore Cancer Center, Phoenix, Arizona, United States|Arizona Oncology, Tucson, Arizona, United States|California Pacific Medical Center- Pacific Campus, San Francisco, California, United States|Olive View - UCLA Medical Center, Sylmar, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|University of Colorado Denver, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, United States|Rocky Mountain Cancer Centers, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers, Littleton, Colorado, United States|Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States|Rocky Mountain Cancer Centers, Longmont, Colorado, United States|Rocky Mountain Cancer Centers, Parker, Colorado, United States|Rocky Mountain Cancer Centers, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers, Thornton, Colorado, United States|AdventHealth Cancer Institute, Orlando, Florida, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Rush University Cancer Center - Chicago and Innovation, Chicago, Illinois, United States|Des Moines Oncology Research Association, Des Moines, Iowa, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Maryland Oncology Hematology, P.A., Silver Spring, Maryland, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|Minnesota Oncology Hematology, PA, Saint Paul, Minnesota, United States|Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States|Methodist Estabrook Cancer Center, Omaha, Nebraska, United States|Women's Cancer Center of Nevada, Las Vegas, Nevada, United States|Center of Hope at Renown Medical Center, Reno, Nevada, United States|MD Anderson Cancer Center at Cooper, Camden, New Jersey, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Miami Valley Hospital South, Centerville, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Northwest Cancer Specialists, PC, Portland, Oregon, United States|West Penn OB/GYN, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Abington Hospital- Asplundh Cancer Pavilion, Willow Grove, Pennsylvania, United States|Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Sanford Gynecologic Oncology Clinic, Sioux Falls, South Dakota, United States|Texas Oncology Austin-Balcones, Austin, Texas, United States|Texas Oncology Austin-Midtown, Austin, Texas, United States|Texas Oncology Austin-North Austin, Austin, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology-Fort Worth, Fort Worth, Texas, United States|The University of Texas Medical School at Houston, Houston, Texas, United States|Texas Oncology-McAllen, McAllen, Texas, United States|Texas Oncology San Antonio Medical Center, San Antonio, Texas, United States|Texas Oncology - Sugar Land, Sugar Land, Texas, United States|Texas Oncology, The Woodlands, Texas, United States|Texas Oncology-Tyler, Tyler, Texas, United States|Texas Oncology-Deke Slayton Cancer Center, Webster, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Carilion Clinic-Gynecologic Oncology, Roanoke, Virginia, United States|Multicare Institute for Research and Innovation, Tacoma, Washington, United States|KH der Barmherzigen Brüder Graz, Graz, Austria|Univ.-Klinik für Gynäkologie und Geburtshilfe, Graz, Austria|Univ.-Klinik für Gynäkologie und Geburtshilfe, Innsbruck, Innsbruck, Austria|Landesfrauenklinik Salzburg, Salzburg, Austria|Imelda Ziekenhuis Bonheiden, Bonheiden, Belgium|Cliniques Universitaires Saint Luc, Institut Roi Albert II, Brussel, Belgium|Grand Hôpital de Charleroi, Oncologie-Hématologie, Charleroi, Belgium|AZ Maria Middelares, Clinical Trial Unit Medical Oncology - Integrated Cancer Center Ghent, Gent, Belgium|UZ Gent, Gent, Belgium|University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium|CHU Ambroise Paré, Mons, Belgium|CHU UCL Namur - Site Ste Elisabeth, Namur, Belgium|UCL-CUL Mont Godinne, Yvoir, Belgium|Onkologická Klinika Fakultní nemocnice Olomouc, Olomouc, Czechia|University Hospital Ostrava, Ostrava-Poruba, Czechia|Gynekologicko-porodnická klinika, Fakultní nemocnice Královské Vinohrady, Praha 10, Czechia|Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha 2, Czechia|Gynekologicko-porodnické oddělení - Nemocnice České Budějovice a.s., České Budějovice, Czechia|Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Klinik für Gynäkologie, Berlin, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Horst-Schmidt-Kliniken, Gynecology and Gynecologic, Oncology Department, Wiesbaden, Germany|Nőgyógyászati Osztály, Országos Onkológiai Intézet, Budapest, Hungary|Szuleszeti és Nogyogyaszati Klinika, Debrecen, Hungary|Hillel Yaffe Medical Center, Hadera, Israel|Saare Zedek Medical Center - Gyneco-Oncology, Jerusalem, Israel|Oncology Institute, Galilee Medical Center, Nahariya, Israel|Gyneco-Oncology Chaim Sheba Medical Center, Ramat Gan, Israel|Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii, Bologna, Italy|Presidio Ospedaliero Antonio Perrino - ASL Brindisi, Brindisi, Italy|ASST Lecco - Ospedale Manzoni, Dipartimento Oncologico, Lecco, Italy|Dipartimento Medicina e Chirurgia, Università Milano-Bicocca, Direttore Programma Ginecologia Oncologica, Istituto Europeo Oncologia, Milano, Italy|IRCCS Ospedale San Raffaele, U.O. Ginecologia-Ematologia e TMO, Milano, Italy|Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy|Fondazione Policlinico Universitario Gemelli, Roma, Italy|University Saint Anna, Torino, Italy|Oddział Kliniczny Chirurgii Ogólnej i Onkologicznej, Szpital Św. Rafała, Kraków, Poland|Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie, Oddział Kliniczny Onkologii i Immunoonkologii z Ośrodkiem Dziennym Terapii Onkologicznej, Olsztyn, Poland|Oddział Ginekologii Onkologicznej Katedry i Kliniki Onkologii Uniwersytetu Medycznego w Poznaniu, Poznań, Poland|Servicio de Oncología Médica, Hospital Universitario Quirón Dexeus, Barcelona, Spain|lnstitut Catala d'Oncologia, Hospital Universitario Dr. Josep Trueta, Servicio de Oncologia,, Girona, Spain|Clinica Universidad de Navarra en Madrid, Madrid, Spain|Hospital MD Anderson Cancer Center, Madrid, Spain|Hospital Universitario Ramon y Cajal, Servicio de Oncologia Médica, Madrid, Spain|Hospital 12 de Octubre. Servicio Oncología Médica, Madrid, Spain|Fundació Institut d'Investigació Sanitària Illes Balears - IdISBa, Hospital Universitari Son Espases, Palma De Mallorca, Spain|Gynecological Tumor Center, University Hospital Basel, Basel, Switzerland|IOSI Bellinzona, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland|Kantonsspital Frauenfeld - Frauenklinik, Frauenfeld, Switzerland|UniversitätsSpital Zürich - Klinik für Gynäkologie, Zürich, Switzerland
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03940196
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 11:
  NCT Number:          NCT03995667
  Title:            Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Extensive Stage Lung Small Cell Carcinoma|Limited Stage Lung Small Cell Carcinoma|Stage I Lung Cancer AJCC v8|Stage IA1 Lung Cancer AJCC v8|Stage IA2 Lung Cancer AJCC v8|Stage IA3 Lung Cancer AJCC v8|Stage IB Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8
  Interventions:        Other: Questionnaire Administration|Device: Tumor Treating Fields Therapy
  Outcome Measures:       Incidence of small cell lung cancer (SCLC) brain metastases at 6 months|Incidence of SCLC brain metastases at 12 months|Overall survival|Incidence of TTfield related adverse events|Incidence of cognitive adverse events (AEs) using Mini Mental State Exam (MMSE)|Change in quality of life over time: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30)|Incidence of SCLC brain metastases
  Sponsor/Collaborators:    OHSU Knight Cancer Institute|NovoCure Ltd.|Oregon Health and Science University
  Gender:            All
  Age:             22 Years and older   (Adult, Older Adult)
  Phases:            Phase 2
  Enrollment:          106
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:          STUDY00018029|NCI-2020-00574
  Start Date:          June 11, 2019
  Primary Completion Date:   June 20, 2021
  Completion Date:       December 30, 2022
  First Posted:         June 24, 2019
  Results First Posted:
  Last Update Posted:      December 16, 2020
  Locations:          Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States|University of Washington Medical Center, Seattle, Washington, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03995667
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 12:
  NCT Number:          NCT01971281
  Title:            Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)
  Acronym:
  Status:            Unknown status
  Study Results:        No Results Available
  Conditions:          Pancreatic Adenocarcinoma
  Interventions:        Device: NovoTTF-100L|Drug: Gemcitabine|Drug: nab-Paclitaxel
  Outcome Measures:       Adverse Events Severity and Frequency|Feasibility based on compliance with TTFields therapy|Progression Free Survival|Overall Survival|1 Year Survival Rate|6 Month Progression-Free Survival Rate|Overall Response Rate based on RECIST (Response Evaluation Criteria in Solid Tumors) criteria 1.1.
  Sponsor/Collaborators:    NovoCure Ltd.
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 1|Phase 2
  Enrollment:          40
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          EF-20
  Start Date:          November 2013
  Primary Completion Date:   December 2017
  Completion Date:       December 2017
  First Posted:         October 29, 2013
  Results First Posted:
  Last Update Posted:      September 13, 2017
  Locations:          Hospital General Universitario de Elche, Elche, Spain|Hospital 12 de Octubre, Madrid, Spain|Ramon Y Cajal, Madrid, Spain|Hospital Universitario Carlos Haya, Malaga, Spain|Hospital Universitario Santander, Santander, Spain|HFR-Hopital Cantonal, Freiburg, Switzerland
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT01971281
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 13:
  NCT Number:          NCT04281576
  Title:            Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Gastric Cancer|GastroEsophageal Cancer
  Interventions:        Device: NovoTTF-100L(P)|Drug: Oxaliplatin|Drug: Capecitabine|Drug: Trastuzumab
  Outcome Measures:       Objective response rate|Progression-free survival|Overall survival|Disease control rate|Time to progression|Duration of response|12 month overall survival rate|Severity and frequency of adverse events
  Sponsor/Collaborators:    NovoCure GmbH|Zai Lab (Shanghai) Co., Ltd.|NovoCure Ltd.
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Not Applicable
  Enrollment:          28
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          EF-31 / ZL-8301-001
  Start Date:          December 19, 2019
  Primary Completion Date:   September 2021
  Completion Date:       September 2021
  First Posted:         February 24, 2020
  Results First Posted:
  Last Update Posted:      June 25, 2020
  Locations:          Queen Mary Hospital, Hong Kong, Hong Kong
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT04281576
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 14:
  NCT Number:          NCT03405792
  Title:            Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)
  Acronym:           2-THE-TOP
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma|Glioblastoma, WHO Grade IV
  Interventions:        Drug: Temozolomide (TMZ)|Device: Optune System|Drug: Pembrolizumab
  Outcome Measures:       Progression-free survival between the groups|Number of adverse events|Overall Survival (OS)|Augmentation of TTFields-initiated glioma-specific immune reaction by pembrolizumab
  Sponsor/Collaborators:    University of Florida|NovoCure Ltd.
  Gender:            All
  Age:             18 Years to 80 Years   (Adult, Older Adult)
  Phases:            Phase 2
  Enrollment:          32
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          IRB201702270|OCR16397
  Start Date:          February 23, 2018
  Primary Completion Date:   February 2023
  Completion Date:       February 2023
  First Posted:         January 23, 2018
  Results First Posted:
  Last Update Posted:      February 9, 2021
  Locations:          University of Florida Health, Gainesville, Florida, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03405792
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 15:
  NCT Number:          NCT04218019
  Title:            Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation
  Acronym:           GERAS
  Status:            Not yet recruiting
  Study Results:        No Results Available
  Conditions:          Newly Diagnosed Glioblastoma in Patients ≥70 Years
  Interventions:        Device: TTFields
  Outcome Measures:       Safely conducted therapy rate (SCTR)|Number of participants with treatment related adverse events as assessed by CTCAE V 5.0.|Progression-free survival|The correlation between the Optune device usage and the health-related quality of life of elderly patients and families undergoing this therapy in combination with radiotherapy/chemo-radiotherapy.
  Sponsor/Collaborators:    Juergen Debus|University Hospital Heidelberg
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 2
  Enrollment:          68
  Funded Bys:          Other
  Study Type:          Interventional
  Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          GERAS
  Start Date:          August 1, 2021
  Primary Completion Date:   February 1, 2022
  Completion Date:       February 1, 2023
  First Posted:         January 6, 2020
  Results First Posted:
  Last Update Posted:      September 11, 2020
  Locations:          University Hospital of Heidelberg, Radiation Oncology, Heidelberg, Germany
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT04218019
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 16:
  NCT Number:          NCT03906448
  Title:            FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma
  Acronym:           FORWARD
  Status:            Terminated
  Study Results:        No Results Available
  Conditions:          Astrocytoma, Grade II|Astrocytoma, Grade III
  Interventions:        Combination Product: TTFields with adjuvant temozolomide
  Outcome Measures:       Overall Survival
  Sponsor/Collaborators:    University of Florida|NovoCure Ltd.
  Gender:            All
  Age:             18 Years to 99 Years   (Adult, Older Adult)
  Phases:            Phase 2
  Enrollment:          2
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          IRB201800600|OCR17711
  Start Date:          May 20, 2019
  Primary Completion Date:   June 8, 2020
  Completion Date:       June 8, 2020
  First Posted:         April 8, 2019
  Results First Posted:
  Last Update Posted:      June 17, 2020
  Locations:          UF Health at the University of Florida, Gainesville, Florida, United States|USF Health Morsani College of Medicine-Moffitt Cancer Center, Tampa, Florida, United States|Henry Ford Health System, Detroit, Michigan, United States|Brown University-Rhode Island Hospital, Providence, Rhode Island, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03906448
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 17:
  NCT Number:          NCT04221503
  Title:            Niraparib/TTFields in GBM
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma|Recurrent Glioblastoma|GBM
  Interventions:        Drug: Niraparib|Device: Optune|Procedure: Planned surgical resection
  Outcome Measures:       Disease control, defined as achievement of either CR, PR, or SD, as defined by modified Response Assessment in Neuro-Oncology (mRANO) criteria.|Number of AEs (Adverse Events)|Duration of disease control.|Objective radiographic response (ORR)|Progression-free survival (PFS)|Overall survival (OS)
  Sponsor/Collaborators:    University of Pennsylvania|Tesaro, Inc.|NovoCure Ltd.
  Gender:            All
  Age:             22 Years and older   (Adult, Older Adult)
  Phases:            Phase 2
  Enrollment:          30
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          03319
  Start Date:          December 30, 2019
  Primary Completion Date:   December 2025
  Completion Date:       December 2025
  First Posted:         January 9, 2020
  Results First Posted:
  Last Update Posted:      July 2, 2020
  Locations:          Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT04221503
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 18:
  NCT Number:          NCT02831959
  Title:            Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fileds (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
  Interventions:        Device: NovoTTF-100M device|Other: Best Standard of Care
  Outcome Measures:       Time to intracranial progression|Time to neurocognitive failure|Overall survival|Radiological response in the brain|Time to second intracranial progression|Time to first and second intracranial progression evaluated in two cohorts, 1-4 brain metastases and 5-10 brain metastases.|Rate of intracranial progression at 2, 4, 6, 8, 10, 12 months|Time to distant progression|Rate of decline in cognitive function at 2, 4, 6, 8, 10, 12 months|Neurocognitive failure-free survival|Quality of Life using the EORTC QLQ C30 with BN20 addendum|Toxicity during NovoTTF-100M treatment based on incidence and severity of treatment emergent adverse events as evaluated using the CTCAE version 4.0
  Sponsor/Collaborators:    NovoCure GmbH|NovoCure Ltd.
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 3
  Enrollment:          270
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          EF-25 METIS
  Start Date:          July 2016
  Primary Completion Date:   September 2022
  Completion Date:       September 2022
  First Posted:         July 13, 2016
  Results First Posted:
  Last Update Posted:      January 6, 2021
  Locations:          University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Mayo Clinic Phoenix, Phoenix, Arizona, United States|MemorialCare Cancer Institute, Long Beach, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Redwood City, Redwood City, California, United States|Dignity Health - Mercy Cancer Centers, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Sharp HealthCare, San Diego, California, United States|University of California, San Francisco, California, United States|Mayo Clinic, Jacksonville, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|UF Health Cancer Center, Orlando, Florida, United States|BRCR Medical Center INC, Plantation, Florida, United States|Piedmont Brain Tumor Center, Atlanta, Georgia, United States|CDH-Delnor Health System, Warrenville, Illinois, United States|Ochsner Health System, New Orleans, Louisiana, United States|Willis-Knighton Cancer Center, Shreveport, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|John Nasseff Neuroscience Institute ANW Brain Tumor Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Ellis Fischel Cancer Center, University of Missouri Healthcare, Columbia, Missouri, United States|Oncology Research  Mercy Research, Saint Louis, Missouri, United States|Renown Regional Medical Center, Reno, Nevada, United States|MD Anderson Cancer Center at Cooper, Camden, New Jersey, United States|UNC - Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Vidant Medical Center, Greenville, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|West Cancer Center, Germantown, Tennessee, United States|Houston Methodist Hospital, Houston, Texas, United States|Texas Oncology, McKinney, Texas, United States|Texas Oncology, Plano, Texas, United States|University of Washington Medical Center, Seattle, Washington, United States|Medizinische Universität Innsbruck, Innsbruck, Austria|UMHAT Sv. Ivan Rilski EAD, Department of Medical Oncology, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Sofiamed, Department of Medical Oncology, Sofia, Bulgaria|Cancercare Manitoba, Winnipeg, Manitoba, Canada|Notre-Dame Hospital CHUM, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Le CIUSSS de I'Est-de-L'ile de Montreal, Montréal, Quebec, Canada|Radiochirugia Zagreb, Sveta Nedelja, Croatia|University Hospital Lille, Lille, France|Clairval Hospital Center, Marseille, France|Hopital Pitié-Salpétriere, Paris, France|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Dr. Senckenbergisches Institut für Neuroonkologie, Zentrum der Neurologie und Neurochirurgie, Frankfurt am main, Germany|Universitätsklinikum Halle (Saale), Klinik für Innere Medizin IV, Hämatologie / Onkologie, Halle (Saale), Germany|Geza Hetenyi Hospital-Clinic of Jasz-Nagykun-Szolnok County, Szolnok, Hungary|Rambam Medical Center, Haifa, Israel|Hadassah Medical Organization, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Sourasky Medical Center, Tel Aviv, Israel|A.O.S.G. Moscati Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialità, Avellino, Italy|Azienda Socio Sanitaria Territoriale di Lecco, Lecco, Italy|University Hospital of Messina AOU Policlinico "G. Martino", Messina, Italy|Marek Harat Private Practice, Neurosurgery and Radiation Oncology, Bydgoszcz, Poland|University Clinical Center, Gdańsk, Poland|Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland|Center for Neuro-oncology, Neurosurgery Clinic, Clinical Center of Serbia, Belgrad, Serbia|Catalan Institute of Oncology, Barcelona, Spain|Clinica Universidad de Navarra, Pamplona, Spain
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT02831959
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 19:
  NCT Number:          NCT02663271
  Title:            TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma Multiforme|Glioblastoma|Malignant Glioma|GBM
  Interventions:        Drug: Bevacizumab|Device: Optune|Other: Brain MRI|Other: Quality of Life Questionnaires
  Outcome Measures:       Progression-free survival between the groups|Number of adverse events|Karnofsky Performance Scale|Mini-Mental Status Exam|Response Assessment in Neuro-Oncology (RANO) Measurement Form
  Sponsor/Collaborators:    University of Florida|NovoCure Ltd.
  Gender:            All
  Age:             22 Years and older   (Adult, Older Adult)
  Phases:            Phase 2
  Enrollment:          18
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          IRB201600074|OCR14874
  Start Date:          August 2016
  Primary Completion Date:   March 15, 2022
  Completion Date:       March 15, 2022
  First Posted:         January 26, 2016
  Results First Posted:
  Last Update Posted:      November 3, 2020
  Locations:          University of Florida, Gainesville, Florida, United States|Washington University, Saint Louis, Missouri, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT02663271
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 20:
  NCT Number:          NCT02743078
  Title:            Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
  Acronym:
  Status:            Terminated
  Study Results:        Has Results
  Conditions:          Glioblastoma|Glioma|Gliosarcoma
  Interventions:        Drug: Bevacizumab|Device: TTFields Therapy
  Outcome Measures:       Overall Survival at 6 Months|Overall Survival (OS)|Progression-Free Survival|Number of Participants With Partial or Complete Response|Number of Participants With Grade 3+ Treatment-related Adverse Events
  Sponsor/Collaborators:    RTOG Foundation, Inc.|NovoCure Ltd.
  Gender:            All
  Age:             22 Years and older   (Adult, Older Adult)
  Phases:            Phase 2
  Enrollment:          3
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          RTOG 3503|RF 3503
  Start Date:          May 9, 2017
  Primary Completion Date:   October 15, 2019
  Completion Date:       October 15, 2019
  First Posted:         April 19, 2016
  Results First Posted:     November 17, 2020
  Last Update Posted:      November 17, 2020
  Locations:          University of California, San Diego, La Jolla, California, United States|University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, California, United States|Miami Cancer Institute at Baptist Health, Miami, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Rochester, Rochester, New York, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States
  Study Documents:       "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02743078/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02743078/ICF_001.pdf
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT02743078
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 21:
  NCT Number:          NCT02244502
  Title:            Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)
  Acronym:
  Status:            Unknown status
  Study Results:        No Results Available
  Conditions:          Ovarian Carcinoma
  Interventions:        Device: NovoTTF-100L(O)|Drug: Paclitaxel
  Outcome Measures:       Adverse Events Severity and Frequency|Number of patients prematurely discontinuing TTFields due to Skin Toxicity|Progression Free Survival|Overall Survival|1 Year Survival Rate|Overall Radiological Response Rate and Duration of Response|CA-125 Response Rate and Duration of Response|Patients' compliance with TTFields Therapy
  Sponsor/Collaborators:    NovoCure Ltd.
  Gender:            Female
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 1|Phase 2
  Enrollment:          31
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          EF-22
  Start Date:          September 2014
  Primary Completion Date:   December 2016
  Completion Date:       December 2016
  First Posted:         September 19, 2014
  Results First Posted:
  Last Update Posted:      September 21, 2016
  Locations:          Leuven, Belgium|Charité - Universitätsmedizin Berlin, Berlin, Germany|Hospitale Universitario 12 de Octubre, Madrid, Spain|Ospedale San Giovanni, Bellinzona, Switzerland|Kantonsspital Graubünden, Chur, Switzerland
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT02244502
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 22:
  NCT Number:          NCT03033992
  Title:            Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Malignant Glioma|Ependymoma
  Interventions:        Device: Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields)
  Outcome Measures:       The feasibility of treatment with the Optune device in pediatric patients with recurrent/refractory/progressive supratentorial malignant glioma and ependymoma.|The Optune device treatment-related toxicities in children with recurrent/refractory/progressive supratentorial malignant glioma and ependymoma.|The Response Rate|The Event-Free Survival|The association of anti-tumor activity with compliance in Optune device use within the context of a small feasibility study.|The association between the Optune device usage and the health-related quality of life of children and families undergoing this therapy.|The association of apparent diffusion coefficient (ADC) values within the tumor and correlate with response to Optune treatment and EFS.
  Sponsor/Collaborators:    Pediatric Brain Tumor Consortium|National Cancer Institute (NCI)
  Gender:            All
  Age:             5 Years to 21 Years   (Child, Adult)
  Phases:            Not Applicable
  Enrollment:          25
  Funded Bys:          Other|NIH
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          PBTC-048|5UM1CA081457
  Start Date:          April 4, 2017
  Primary Completion Date:   April 2021
  Completion Date:       April 2021
  First Posted:         January 27, 2017
  Results First Posted:
  Last Update Posted:      February 15, 2021
  Locations:          Children's Hospital Los Angeles, Los Angeles, California, United States|Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Stewart Goldman, Chicago, Illinois, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03033992
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 23:
  NCT Number:          NCT04221061
  Title:            A Pilot Study Evaluating in Vivo PARP-1 Expression with18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Glioblastoma
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma
  Interventions:        Drug: 18F-FluorThanatrace
  Outcome Measures:       Evaluate uptake of [18F]FTT in recurrent glioblastoma after initiation of TTFields therapy.|Correlate [18F]FTT uptake measures with Homologous recombination deficiency (HRD) status or other markers of "BRCAness".
  Sponsor/Collaborators:    University of Pennsylvania
  Gender:            All
  Age:             22 Years and older   (Adult, Older Adult)
  Phases:            Early Phase 1
  Enrollment:          12
  Funded Bys:          Other
  Study Type:          Interventional
  Study Designs:        Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic
  Other IDs:          833963
  Start Date:          February 20, 2020
  Primary Completion Date:   December 2, 2021
  Completion Date:       December 2, 2022
  First Posted:         January 9, 2020
  Results First Posted:
  Last Update Posted:      February 12, 2021
  Locations:          University of Pennsylvania, Philadelphia, Pennsylvania, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT04221061
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 24:
  NCT Number:          NCT03780569
  Title:            TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM
  Acronym:
  Status:            Unknown status
  Study Results:        No Results Available
  Conditions:          Glioblastoma Multiforme
  Interventions:        Device: NovoTTF-200A|Radiation: Radiotherapy|Drug: Temozolomide
  Outcome Measures:       Safety of concomitant Radiotherapy/Temozolomide with NovoTTF-200A: The incidence of Radiotherapy treatment delays during concomitant Radiotherapy/Temozolomide/NovoTTF-200A will be documented including severity and relationship to NovoTTF-200A.|Progression free survival|Overall survival|Adverse events, severity and frequency
  Sponsor/Collaborators:    NovoCure Ltd.
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Not Applicable
  Enrollment:          10
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          ICH-1
  Start Date:          April 27, 2017
  Primary Completion Date:   January 2019
  Completion Date:       January 2019
  First Posted:         December 19, 2018
  Results First Posted:
  Last Update Posted:      December 20, 2018
  Locations:          Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03780569
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 25:
  NCT Number:          NCT01755624
  Title:            Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)
  Acronym:
  Status:            Unknown status
  Study Results:        No Results Available
  Conditions:          1-5 Brain Metastases From Non-Small Cell Lung Cancer
  Interventions:        Device: NovoTTF-100A device|Other: Best Standard of Care
  Outcome Measures:       Time to Local and Distant Progression in The Brain|Overall Survival|6-Month Disease Control Rate in The Brain|Neurocognitive Function (MMSE and HVLT)|Quality of life (QLQ-C30 and BN-20)|Overall (systemic) Progression-Free Survival (RECIST Criteria)|Adverse Events Severity and Frequency
  Sponsor/Collaborators:    NovoCure Ltd.
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 2
  Enrollment:          18
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          EF-21
  Start Date:          January 2013
  Primary Completion Date:   July 2017
  Completion Date:       July 2017
  First Posted:         December 24, 2012
  Results First Posted:
  Last Update Posted:      September 21, 2016
  Locations:          Na Homolce Hospital, Prague, Czech Republic|Hopital Neurologique Pierre Wertheimer, Lyon, France|Centre Paul Strauss, Strasbourg, France|Ospedale Lecco, Lecco, Italy|Medical University of Gdańsk, Gdańsk, Poland|Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznan, Poland|ICO L'Hospitalet - Hospital Duran i Reynals, Barcelona, Spain
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT01755624
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 26:
  NCT Number:          NCT03223103
  Title:            Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma
  Interventions:        Drug: Poly-ICLC|Device: Tumor Treating Fields|Biological: Peptides
  Outcome Measures:       Dose-limiting toxicities (DLT)|Toxicity grading using CTCAE scale|The percent Progression Free Survival (PFS)|Overall Survival (OS) Rate|Overall Response Rate
  Sponsor/Collaborators:    Adilia Hormigo|NovoCure Ltd.|Icahn School of Medicine at Mount Sinai
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 1
  Enrollment:          20
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          GCO 17-0566|16-089
  Start Date:          March 1, 2018
  Primary Completion Date:   May 2023
  Completion Date:       May 2023
  First Posted:         July 19, 2017
  Results First Posted:
  Last Update Posted:      September 2, 2020
  Locations:          Icahn School of Medicine at Mount Sinai, New York, New York, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03223103
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 27:
  NCT Number:          NCT03705351
  Title:            Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma|Cancer of Brain|Glioblastoma Multiforme|Brain Tumor
  Interventions:        Device: Tumor Treating Fields|Drug: Temozolomide|Radiation: Radiation Therapy
  Outcome Measures:       Rate of treatment-related adverse events associated with trimodal therapy|Severity of treatment-related adverse events associated with trimodal therapy|Progression-free survival at 6 months and 24 months|Overall Survival Rate
  Sponsor/Collaborators:    Providence Health & Services|University of California, San Francisco|NovoCure Ltd.
  Gender:            All
  Age:             22 Years and older   (Adult, Older Adult)
  Phases:            Phase 1
  Enrollment:          30
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          UNITYGBM01
  Start Date:          December 2, 2019
  Primary Completion Date:   November 1, 2023
  Completion Date:       November 1, 2025
  First Posted:         October 15, 2018
  Results First Posted:
  Last Update Posted:      May 28, 2020
  Locations:          University of California San Francisco, San Francisco, California, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03705351
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 28:
  NCT Number:          NCT03353896
  Title:            NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma
  Acronym:
  Status:            Withdrawn
  Study Results:        No Results Available
  Conditions:          Anaplastic Oligodendroglioma|Oligoastrocytoma|Oligodendroglioma
  Interventions:        Device: Wear novoTTF-200A|Procedure: Quality-of-Life Assessment
  Outcome Measures:       Safety and Tolerability of the NovoTTFields treatment in patients with high risk oligodendroglioma
  Sponsor/Collaborators:    University of Southern California|National Cancer Institute (NCI)|NovoCure Ltd.
  Gender:            All
  Age:             19 Years and older   (Adult, Older Adult)
  Phases:            Not Applicable
  Enrollment:          0
  Funded Bys:          Other|NIH|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          6B-15-1|NCI-2017-02074|EF-OLIGO-15|P30CA014089
  Start Date:          December 15, 2017
  Primary Completion Date:   December 8, 2020
  Completion Date:       December 8, 2020
  First Posted:         November 27, 2017
  Results First Posted:
  Last Update Posted:      December 10, 2020
  Locations:          USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03353896
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 29:
  NCT Number:          NCT02893137
  Title:            Enhancing Optune Therapy With Targeted Craniectomy
  Acronym:
  Status:            Completed
  Study Results:        No Results Available
  Conditions:          Glioblastoma
  Interventions:        Device: Optune|Procedure: Craniectomy
  Outcome Measures:       Frequency of serious adverse events|Overall survival|Progression free survival|Progression free survival at six months|% 1-year survival|Objective response rate|Quality of life|Cumulative corticosteroid dosage|Karnofsky performance score
  Sponsor/Collaborators:    Aarhus University Hospital|NovoCure Ltd.|University of Aarhus
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 1
  Enrollment:          15
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          54762
  Start Date:          October 1, 2016
  Primary Completion Date:   May 31, 2019
  Completion Date:       May 31, 2019
  First Posted:         September 8, 2016
  Results First Posted:
  Last Update Posted:      November 27, 2019
  Locations:          Aarhus University Hospital, Aarhus C, Aarhus, Denmark
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT02893137
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 30:
  NCT Number:          NCT03477110
  Title:            Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma
  Interventions:        Drug: Temozolomide|Radiation: Radiation Therapy|Device: NovoTTF-200A Device|Procedure: Tumor Treating Fields Therapy
  Outcome Measures:       NovoTTF-200A device discontinuation rate due to skin toxicity|Progression-free survival|Overall survival|Event-free survival
  Sponsor/Collaborators:    Sidney Kimmel Cancer Center at Thomas Jefferson University|NovoCure Ltd.|Thomas Jefferson University
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Early Phase 1
  Enrollment:          35
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          17P.346
  Start Date:          May 4, 2018
  Primary Completion Date:   March 2021
  Completion Date:       September 2021
  First Posted:         March 26, 2018
  Results First Posted:
  Last Update Posted:      March 5, 2021
  Locations:          Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03477110
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 31:
  NCT Number:          NCT04397679
  Title:            Partial Brain Radiation Therapy, Temozolomide, Chloroquine, and Tumor Treating Fields Therapy for the Treatment of Newly Diagnosed Glioblastoma
  Acronym:
  Status:            Not yet recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma|Gliosarcoma
  Interventions:        Radiation: 3-Dimensional Conformal Radiation Therapy|Radiation: Intensity-Modulated Radiation Therapy (IMRT)|Drug: Temozolomide|Drug: Chloroquine|Procedure: Tumor Treating Fields Therapy (TTF)
  Outcome Measures:       Proportion of patients who develop a specific acute toxicity (dermatitis)|Incidence of adverse events
  Sponsor/Collaborators:    Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 1
  Enrollment:          10
  Funded Bys:          Other|NIH
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          2018-148
  Start Date:          April 30, 2021
  Primary Completion Date:   March 11, 2022
  Completion Date:       September 11, 2022
  First Posted:         May 21, 2020
  Results First Posted:
  Last Update Posted:      March 1, 2021
  Locations:          Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT04397679
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 32:
  NCT Number:          NCT03687034
  Title:            A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma
  Acronym:
  Status:            Unknown status
  Study Results:        No Results Available
  Conditions:          Glioblastoma
  Interventions:        Drug: Temozolomide|Device: Optune
  Outcome Measures:       Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Maximum tolerated dose|Levels of metabolites|Progression-free survival
  Sponsor/Collaborators:    Leaf Vertical Inc.
  Gender:            All
  Age:             18 Years to 85 Years   (Adult, Older Adult)
  Phases:            Phase 1
  Enrollment:          21
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          Olympian 2
  Start Date:          June 1, 2019
  Primary Completion Date:   September 30, 2019
  Completion Date:       December 31, 2020
  First Posted:         September 27, 2018
  Results First Posted:
  Last Update Posted:      February 26, 2019
  Locations:
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03687034
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 33:
  NCT Number:          NCT04474353
  Title:            Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
  Acronym:
  Status:            Not yet recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma|Newly Diagnosed Glioblastoma
  Interventions:        Device: Optune|Drug: Gadolinium|Drug: Temozolomide|Radiation: Stereotactic radiosurgery (SRS)
  Outcome Measures:       Dose-limiting Toxicity (DLTs)|Acute dose limiting toxicity|Progression-free Survival (PFS) at 6 Months|Overall Survival (OS)
  Sponsor/Collaborators:    Stanford University|NovoCure Ltd.
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 1
  Enrollment:          12
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          IRB-53582|BRN0043
  Start Date:          November 2020
  Primary Completion Date:   May 2023
  Completion Date:       November 2024
  First Posted:         July 16, 2020
  Results First Posted:
  Last Update Posted:      October 22, 2020
  Locations:          Stanford University, Stanford, California, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT04474353
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 34:
  NCT Number:          NCT00749346
  Title:            NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer
  Acronym:
  Status:            Completed
  Study Results:        No Results Available
  Conditions:          Non-small Cell Lung Cancer|NSCLC
  Interventions:        Device: NovoTTF-100L
  Outcome Measures:       Device related toxicity|Time to progression
  Sponsor/Collaborators:    NovoCure Ltd.
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 1|Phase 2
  Enrollment:          42
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          EF-15
  Start Date:          May 2008
  Primary Completion Date:   July 2011
  Completion Date:       July 2011
  First Posted:         September 9, 2008
  Results First Posted:
  Last Update Posted:      September 27, 2011
  Locations:          CCRC, Basel, Switzerland|Kantonspital Graubunden, Chur, Switzerland|Kantonspital Fribourg, Fribourg, Switzerland|Kantonspital Winterthur, Winterthur, Switzerland
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT00749346
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 35:
  NCT Number:          NCT04469075
  Title:            Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma|Skin Toxicity
  Interventions:        Drug: Clindamycin Phosphate|Drug: Triamcinolone Acetonide
  Outcome Measures:       Number of patients without grade 2 or higher skin toxicity|skin-related quality of life
  Sponsor/Collaborators:    Memorial Sloan Kettering Cancer Center
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 2
  Enrollment:          58
  Funded Bys:          Other
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          19-342
  Start Date:          July 9, 2020
  Primary Completion Date:   July 2023
  Completion Date:       July 2023
  First Posted:         July 13, 2020
  Results First Posted:
  Last Update Posted:      April 1, 2021
  Locations:          Northwestern University, Evanston, Illinois, United States|Tufts Medical Center, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT04469075
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 36:
  NCT Number:          NCT03980249
  Title:            Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
  Acronym:
  Status:            Not yet recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma|Glioblastoma Multiforme
  Interventions:        Drug: Carvedilol
  Outcome Measures:       Survival curve of overall survival|Survival curve of progression free survival|Quantify Circulating Tumor Cells (CTCs)
  Sponsor/Collaborators:    West Virginia University|NovoCure Ltd.|West Virginia Clinical and Translational Science Institute
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Early Phase 1
  Enrollment:          30
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          WVU020318
  Start Date:          September 2020
  Primary Completion Date:   December 2021
  Completion Date:       June 2022
  First Posted:         June 10, 2019
  Results First Posted:
  Last Update Posted:      November 4, 2019
  Locations:          WVU Cancer Institute - Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
  Study Documents:       "Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/49/NCT03980249/ICF_000.pdf
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03980249
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 37:
  NCT Number:          NCT03194971
  Title:            NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma
  Interventions:        Other: Tumor samples from patients treated with TTFields at initial diagnosis.|Device: Tumor samples from patients treated with TTFields at tumor recurrence.
  Outcome Measures:       Number of mitotically active cells|Number of mitotically inactive cells|Mitotic Ratio
  Sponsor/Collaborators:    Medical College of Wisconsin
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:
  Enrollment:          20
  Funded Bys:          Other
  Study Type:          Observational
  Study Designs:        Observational Model: Other|Time Perspective: Retrospective
  Other IDs:          PRO00017446
  Start Date:          June 1, 2017
  Primary Completion Date:   May 31, 2021
  Completion Date:       May 31, 2022
  First Posted:         June 21, 2017
  Results First Posted:
  Last Update Posted:      December 16, 2020
  Locations:          Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03194971
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 38:
  NCT Number:          NCT03607682
  Title:            Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer
  Acronym:
  Status:            Terminated
  Study Results:        Has Results
  Conditions:          Extensive Stage Small Cell Lung Carcinoma
  Interventions:        Procedure: Tumor Treating Fields (TTF) Therapy|Device: NovoTTF-200A Device|Other: Quality-of-Life Assessment
  Outcome Measures:       Percentage of Patients Continuing Therapy Until Intracranial Tumor|Time to Intracranial Failure|Overall Survival|Rate of Intracranial Failure|Rate of Decline in Cognitive Function|Time to Neurocognitive Failure|Neurocognitive Failure-free Survival|Evaluate Quality of Life Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30|Incidence of Adverse Events
  Sponsor/Collaborators:    Vanderbilt-Ingram Cancer Center|NovoCure Ltd.
  Gender:            All
  Age:             22 Years and older   (Adult, Older Adult)
  Phases:            Not Applicable
  Enrollment:          2
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          VICC THO 1747|NCI-2018-01428
  Start Date:          September 5, 2018
  Primary Completion Date:   June 2, 2020
  Completion Date:       July 13, 2020
  First Posted:         July 31, 2018
  Results First Posted:     August 4, 2020
  Last Update Posted:      August 4, 2020
  Locations:          Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
  Study Documents:       "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03607682/Prot_SAP_000.pdf
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03607682
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 39:
  NCT Number:          NCT04223999
  Title:            Improving Tumor Treating Fields Treatment for Brain Cancer Patients With Skullremodeling Surgery (Neurosurgery)
  Acronym:           OptimalTTF-2
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Recurrent Glioblastoma
  Interventions:        Procedure: Skullremodeling surgery|Other: Control
  Outcome Measures:       OS12|Median OS|Median PFS|OS24|OS36|PFS6|ORR|Standardised and verified quality of life assessment questionnaires (QLQ-C30 and QLQ-BN20) for cancer and brain tumor patients.|Steroid dose|KPS|AE
  Sponsor/Collaborators:    Anders Rosendal Korshøj|NovoCure GmbH|Odense University Hospital|University of Aarhus
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 2
  Enrollment:          70
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:          150919V1|68928/1-10-72-214-19|658876/1-16-02-277-19|2019081231
  Start Date:          October 1, 2020
  Primary Completion Date:   March 1, 2023
  Completion Date:       March 1, 2024
  First Posted:         January 13, 2020
  Results First Posted:
  Last Update Posted:      November 5, 2020
  Locations:          Nikola Mikic, Aarhus, Denmark
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT04223999
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 40:
  NCT Number:          NCT00379470
  Title:            Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)
  Acronym:
  Status:            Completed
  Study Results:        No Results Available
  Conditions:          Recurrent Glioblastoma Multiforme
  Interventions:        Device: NovoTTF-100A
  Outcome Measures:       Overall Survival|Progression free survival at 6 months (PFS6)|Median Time to Disease Progression (TTP)|% 1-year survival|Radiological response (Macdonald criteria)|Quality of life assessment (EORTC QLQ-C30)|Adverse events severity and frequency
  Sponsor/Collaborators:    NovoCure Ltd.
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 3
  Enrollment:          236
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          EF-11
  Start Date:          September 2006
  Primary Completion Date:   November 2009
  Completion Date:       January 2011
  First Posted:         September 21, 2006
  Results First Posted:
  Last Update Posted:      May 1, 2012
  Locations:          Northwestern University, Chicago, Illinois, United States|University of Illinois in Chicago, Chicago, Illinois, United States|Evanston Northwestern Healthcare, Evanston, Illinois, United States|Boston University Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|NJ Neuroscience Institute - JFK Medical Center, Edison, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|University of Virginia, Charlottesville, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|University Hospital Graz, Graz, Austria|FN Brno - Masaryk University, Brno, Czech Republic|Na Homolce Hospital, Prague, Czech Republic|Hospital of Neurology Lyon - University Claude Bernard Lyon 1, Lyon, France|Group Hospitals Pitie-Salpetriere, Paris, France|University Hospital Augsburg, Augsburg, Germany|University Medical Center Hamburg-Eppendorf, Hamburg, Germany|University Hospital of Schleswig-Holstein, Kiel, Germany|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT00379470
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 41:
  NCT Number:          NCT00916409
  Title:            Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
  Acronym:
  Status:            Completed
  Study Results:        No Results Available
  Conditions:          Glioblastoma Multiforme
  Interventions:        Device: NovoTTF-100A device|Drug: Temozolomide
  Outcome Measures:       Progression Free Survival (PFS) time|Overall survival (OS)
  Sponsor/Collaborators:    NovoCure Ltd.
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 3
  Enrollment:          700
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          EF-14
  Start Date:          June 2009
  Primary Completion Date:   December 2016
  Completion Date:       March 2017
  First Posted:         June 9, 2009
  Results First Posted:
  Last Update Posted:      April 10, 2017
  Locations:          University of Alabama at Birmingham, Birmingham, Alabama, United States|Barrow Neurology Clinics, Phoenix, Arizona, United States|City of Hope, Duarte, California, United States|University of California San Diego Moores Cancer Center (UCSD), La Jolla, California, United States|University of Southern California (USC), Los Angeles, California, United States|University of Colorado Denver, Aurora, Colorado, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Emory University, Winship Cancer Institute, Atlanta, Georgia, United States|University of Illinois at Chicago (UIC), Chicago, Illinois, United States|University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Maine Medical Center, Scarborough, Maine, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School of Medicine, Division of Oncology, St. Louis, Missouri, United States|New Jersey Neuroscience Center - JFK Medical Center, Edison, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai Medical Center, Department of Neurosurgery, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|The Ohio State University Arthur G. James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States|Geisinger Health System, Danville, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Baylor, Dallas, Texas, United States|Methodist Hospital, Houston, Texas, United States|Methodist Neurological Institute, Houston, Texas, United States|The University of Texas Health Science Center at Houston (UTHSC), Houston, Texas, United States|Scott and White Healthcare, Temple, Texas, United States|Memorial Hermann The Woodlands, The Woodlands, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States|University Hospital Graz, Graz, Austria|Medical University of Vienna, Vienna, Austria|SMZ-Süd/Kaiser-Franz-Josef-Spital, Vienna, Austria|Tom Baker Cancer Center, Calgary, Alberta, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Juravinski Cancer Centre, Hamilton,, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Notre-Dame Hospital (CHUM), Montreal, Quebec, Canada|Montreal Neurological Institute, Montreal, Quebec, Canada|McGill - Gerald Bronfman Centre for Clinical Research in Oncology -, Montreal, Quebec, Canada|(CHUS) Centre Hospitalier Universitaire de Sherbrooke, Service de Neurochirurgie, Sherbrooke, Quebec, Canada|Na Homolce Hospital, Prague, Czech Republic|CHU Amiens Sud-Salouel, Amiens, France|CHU Angers, Angers, France|Hôpital Saint André Centre Hospitalier Universitaire (CHU) des Hôpitaux de Bordeaux, Bordeaux, France|Hospital of Neurology Pierre Wertheimer, Lyon, France|Group Hospitals Pitie-Salpetriere, Paris, France|Centre Hospitalo-Universitaire de Toulouse Purpan, Toulouse, France|University Medical Center Hamburg-Eppendorf, Hamburg, Germany|Medical University Heidelberg, Heidelberg, Germany|University Hospital of Schleswig-Holstein, Kiel, Germany|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Az. Ospedaliero-Universitaria - Ospedali Riuniti, Ancona, Italy|Ospedale Lecco, Lecco, Italy|C. Besta Neurological Institute, Milan, Italy|Foundation Hospital Greater Policlinico, Milan, Italy|Istituti Fisioterapici Ospitalieri - Istituto Nazionale dei Tumori Regina Elena, Rome, Italy|Asan Medical Center, Asan, Korea, Republic of|Yeungnam University Hospital, Daegu, Korea, Republic of|Chungnam National University Hospital (CNUH), Daejeon, Korea, Republic of|Samsung Medical Center (SMC), Seoul, Korea, Republic of|Seoul National University Bundang Hospital (SNUBH), Seoul, Korea, Republic of|Seoul National University Hospital (SNUH), Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital (CMC Seoul), Seoul, Korea, Republic of|Yonsei University Severance Hospital (YUHS), Seoul, Korea, Republic of|Ajou University Hospital (AUH), Suwon, Korea, Republic of|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari de Bellvitge-ICO Duran i Reynals, Barcelona, Spain|Fundacion Jimenes Diaz, Madrid, Spain|Hospital 12 de Octubre, Servicio de Oncología Médica, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Karolinska Institute, Stockholm, Sweden|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|UniversitätsSpital Zürich, Zurich, Switzerland
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT00916409
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 42:
  NCT Number:          NCT01894061
  Title:            NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
  Acronym:
  Status:            Completed
  Study Results:        No Results Available
  Conditions:          Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor
  Interventions:        Biological: Bevacizumab|Device: NovoTTF-l00A|Other: Quality of Life Assessment
  Outcome Measures:       Progression Free Survival (PFS)|Objective response rate based on RANO Criteria|Number of patients that experience toxicities with this combination of therapies|Median overall survival|To assess time-to-progression|Neurocognitive function (NCF)|Quality of Life (QOL)
  Sponsor/Collaborators:    Case Comprehensive Cancer Center|NovoCure Ltd.|National Cancer Institute (NCI)
  Gender:            All
  Age:             22 Years and older   (Adult, Older Adult)
  Phases:            Phase 2
  Enrollment:          25
  Funded Bys:          Other|Industry|NIH
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          CASE3313
  Start Date:          June 12, 2013
  Primary Completion Date:   July 28, 2019
  Completion Date:       July 28, 2019
  First Posted:         July 9, 2013
  Results First Posted:
  Last Update Posted:      July 24, 2020
  Locations:          University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT01894061
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 43:
  NCT Number:          NCT01925573
  Title:            Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)
  Acronym:
  Status:            Terminated
  Study Results:        No Results Available
  Conditions:          RECURRENT GLIOBLASTOMA|Brain Tumor
  Interventions:        Device: Optune(NOVOTTF-100A)
  Outcome Measures:       Number of Adverse Events with a grade 3 or high toxicity (Primary Measure)
  Sponsor/Collaborators:    University of Maryland, Baltimore|NovoCure Ltd.
  Gender:            All
  Age:             22 Years and older   (Adult, Older Adult)
  Phases:            Not Applicable
  Enrollment:          7
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          HP-00056719
  Start Date:          May 2014
  Primary Completion Date:   August 2019
  Completion Date:       August 2019
  First Posted:         August 19, 2013
  Results First Posted:
  Last Update Posted:      November 4, 2020
  Locations:          Ummc Msgcc, Baltimore, Maryland, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT01925573
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 44:
  NCT Number:          NCT03861598
  Title:            Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma Multiforme|Glioblastoma
  Interventions:        Drug: Carvedilol
  Outcome Measures:       Identify the correlation between our new RT-qPCR assay for circulating tumor cells and the change in responses in patients on treatment to MRI results.|Evaluate response with the addition of carvedilol to standard chemotherapy in the second line treatment in glioblastoma multiforme|Evaluate incidents of adverse events during the time subjects are taking carvedilol with chemotherapy
  Sponsor/Collaborators:    West Virginia University|West Virginia Clinical and Translational Science Institute
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Early Phase 1
  Enrollment:          6
  Funded Bys:          Other
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          WVU010318
  Start Date:          July 19, 2019
  Primary Completion Date:   July 1, 2021
  Completion Date:       July 1, 2021
  First Posted:         March 4, 2019
  Results First Posted:
  Last Update Posted:      August 4, 2020
  Locations:          WVU Cancer Institute - Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03861598
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 45:
  NCT Number:          NCT04471844
  Title:            Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM
  Acronym:           EF-32
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma Multiforme
  Interventions:        Device: Optune®
  Outcome Measures:       Overall Survival (OS)|Progression Free Survival (PFS)|1- and 2-year survival rates|Overall Radiological response (ORR)|Next progression-free survival (PFS2)|Progression-free survival at 6 (PFS6) and 12 months (PFS12)|Severity and frequency of adverse events|Pathological changes in resected GBM tumors following study treatments|Quality of Life EORTC Questionnaire|Dependence of overall survival on TTFields dose at the tumor|The NANO scale
  Sponsor/Collaborators:    NovoCure GmbH|NovoCure Ltd.
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Not Applicable
  Enrollment:          950
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          TRIDENT EF-32
  Start Date:          December 8, 2020
  Primary Completion Date:   August 2024
  Completion Date:       August 2026
  First Posted:         July 15, 2020
  Results First Posted:
  Last Update Posted:      February 21, 2021
  Locations:          Grandview Cancer Center, Birmingham, Alabama, United States|St. Joseph's Hospital and Medical Center - Barrow Neurological Institute, Phoenix, Arizona, United States|Mayo Clinic- Arizona, Phoenix, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|Highland Oncology Group, Fayetteville, Arkansas, United States|City of Hope National Medical Center, Duarte, California, United States|TRIO - St. Jude Heritage Healthcare/St. Jude Medical Center, Fullerton, California, United States|University of California at San Diego - Moores Cancer Center, La Jolla, California, United States|Memorial Care Cancer Institute - Long Beach Memorial Medical Center, Long Beach, California, United States|Norris Comprehensive Cancer Center at USC, Los Angeles, California, United States|Cedars - Sinai Medical Center, Los Angeles, California, United States|St. Joseph's Hospital, Orange, California, United States|University of California - Irvine/UCI Medical Center, Orange, California, United States|Kaiser Permanente Redwood City Medical Center, Redwood City, California, United States|Kaiser Permanente Medical Center Sacramento, Sacramento, California, United States|Sharp Memorial Hospital - X-Ray Medical Group Radiation Oncology, San Diego, California, United States|John Wayne Cancer Institute at St. John's Health Center, Santa Monica, California, United States|Stanford Cancer Institute, Stanford, California, United States|University of Colorado Cancer Center Anschutz, Aurora, Colorado, United States|HCA Research Institute - Blue Sky Neurology - Denver, Englewood, Colorado, United States|Yale University Smilow Cancer Hospital, New Haven, Connecticut, United States|Hartford Healthcare Medical Group - Hartford Hospital The Gray Cancer Center, New London, Connecticut, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Baptist Health - Jacksonville, Jacksonville, Florida, United States|Advent Health, Orlando, Florida, United States|Orlando Health UF Health Cancer Center, Orlando, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa, Florida, United States|Piedmont Healthcare Brain Tumor Center, Atlanta, Georgia, United States|The Emory Clinic - Emory Healthcare - Winship Cancer Institute, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Northwestern University, Evanston, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Parkview Cancer Institute - Fort Wayne Radiation Oncology Associates, Fort Wayne, Indiana, United States|The University of Kansas Cancer Center, Overland Park, Kansas, United States|University of Louisville - James Graham Brown Cancer Center, Louisville, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|NeuroMedical Center - DelRicht Research, Baton Rouge, Louisiana, United States|LSU Health Sciences, New Orleans, Louisiana, United States|Ochsner Health System, New Orleans, Louisiana, United States|Maine Medical Partners Neurology - Neurosurgery & Spine Associates, Scarborough, Maine, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Abbott Northwestern Hospital - Givens Brain Tumor Center, Minneapolis, Minnesota, United States|University of Minnesota Health Clinics and Surgery Center, Minneapolis, Minnesota, United States|Health Midwest Ventures Group, Inc - Sarah Cannon HCA Midwest Brain and Spine, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|JFK Medical Center - JFK Brain Tumor Center, Edison, New Jersey, United States|Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States|Northwell Health System Brain Tumor Center, Lake Success, New York, United States|NYU Langone - Laura & Issac Perimutter Cancer Center, New York, New York, United States|Mount Sinai - Icahn School of Medicine, New York, New York, United States|New York Presbyterian - Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina Brain Tumor Program - UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Vidant Medical Center, Greenville, North Carolina, United States|Forsyth Medical Center-Novant Health, Winston-Salem, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University - Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|Case Western - University Hospitals Case Medical Center, Cleveland, Ohio, United States|The James Cancer Hospital and Solove Research Institute - Arthur G James Cancer Hospital, Columbus, Ohio, United States|Providence St Vincent Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Geisinger Health System, Danville, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Health System - Center for Neuro-Oncology - Hillman Cancer Institute, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|MUSC Radiation Oncology Brain & Spine Tumor Program, Charleston, South Carolina, United States|West Cancer Center - Germantown, Germantown, Tennessee, United States|SCRI - Tennessee Oncology, Nashville, Tennessee, United States|Texas Oncology Midtown - Austin Brain Tumor Center, Austin, Texas, United States|Baylor Charles A. Sammons Cancer Center - Baylor University Medical Center, Dallas, Texas, United States|John Peter Smith Health Network - JPS Cancer Center, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|UT Health Mischer Neuroscience - Memorial Herman - UT Neurosciences, Houston, Texas, United States|San Antonio Cancer Institute, San Antonio, Texas, United States|Baylor Scott & White Medical Center, Temple, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|The University of Vermont Medical Center - University of Vermont Cancer Center, Burlington, Vermont, United States|Massey Cancer Center - VCU Medical Center, Richmond, Virginia, United States|UW Medical Center - Alvord Brain Tumor Center, Seattle, Washington, United States|West Virginia University Cancer Institute, Morgantown, West Virginia, United States|Innsbruck State Hospital, Innsbruck, Austria|Kepler University Hospital, Linz, Austria|University Hospital Salzburg, Salzburg, Austria|Hospital Erasme, Brussels, Belgium|CHU de Liege - du Sart Tilman, Liège, Belgium|BC Cancer Agency Vancouver Centre, Vancouver, British Columbia, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHUM Centre de Recherche, Montréal, Quebec, Canada|Universite de Sherbrooke - Sherbrooke Centre Hospitalier Universita, Sherbrooke, Quebec, Canada|Masaryk Memorial Cancer Institute, Brno, Czechia|University Hospital Plzeñ, Pilsen, Czechia|Na Homolce Hospital, Prague, Czechia|Hospital CHU Nice, Nice, France|Hopital de la Pitie Salpetriere, Paris, France|Institut de Cancerologie de l'Ouest, Saint Herblain, France|Institut Universitaire du Cancer de Toulouse, Toulouse, France|Institut Gusatve Roussy, Villejuif, France|University Hospital Berlin, Berlin, Germany|University Hospital Essen, Essen, Germany|University Hospital Tübingen, Tübingen, Germany|Rambam Medical Center, Haifa, Israel|Rabin Medical Center, Petah Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|CHUV - Centre Hospitalier Universitaire Vaudois, Department of Clinical Neurosciences and Oncology, Lausanne, Switzerland|University Hospital Zurich, Zürich, Switzerland
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT04471844
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 46:
  NCT Number:          NCT02343549
  Title:            A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
  Acronym:
  Status:            Terminated
  Study Results:        No Results Available
  Conditions:          Cancer of Brain and Nervous System
  Interventions:        Device: bevacizumab, NovoTTF100A, temozolomide
  Outcome Measures:       Survival at 12 months
  Sponsor/Collaborators:    Ashley Love Sumrall|NovoCure Ltd.|Atrium Health
  Gender:            All
  Age:             22 Years and older   (Adult, Older Adult)
  Phases:            Phase 2
  Enrollment:          13
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          LCI-NEU-NOV-001|00010270
  Start Date:          January 2015
  Primary Completion Date:   July 11, 2020
  Completion Date:       July 11, 2020
  First Posted:         January 22, 2015
  Results First Posted:
  Last Update Posted:      February 3, 2021
  Locations:          Levine Cancer Institute, Charlotte, North Carolina, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT02343549
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 47:
  NCT Number:          NCT03488472
  Title:            Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain
  Acronym:           RAD 1704
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Brain Metastases|Small Cell Lung Cancer
  Interventions:        Device: NovoTTF-200A|Radiation: Stereotactic Radiosurgery (SRS)
  Outcome Measures:       Rate of Distant Metastases|Overall Survival|Local Recurrence|Distant CNS Progression
  Sponsor/Collaborators:    Drexell Hunter Boggs|NovoCure Ltd.|University of Alabama at Birmingham
  Gender:            All
  Age:             18 Years to 99 Years   (Adult, Older Adult)
  Phases:            Not Applicable
  Enrollment:          20
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          IRB-300001201
  Start Date:          August 9, 2019
  Primary Completion Date:   April 2022
  Completion Date:       April 2022
  First Posted:         April 5, 2018
  Results First Posted:
  Last Update Posted:      September 17, 2020
  Locations:          University of Alabama at Birmingham (UAB), Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham, Alabama, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03488472
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 48:
  NCT Number:          NCT03642080
  Title:            MRI Predictors of Response to Tumor Treating Fields
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma Multiforme
  Interventions:
  Outcome Measures:       Progression of disease
  Sponsor/Collaborators:    New York Presbyterian Brooklyn Methodist Hospital
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:
  Enrollment:          48
  Funded Bys:          Other
  Study Type:          Observational
  Study Designs:        Observational Model: Case-Only|Time Perspective: Prospective
  Other IDs:          1137708
  Start Date:          December 1, 2018
  Primary Completion Date:   September 30, 2021
  Completion Date:       December 31, 2023
  First Posted:         August 22, 2018
  Results First Posted:
  Last Update Posted:      December 19, 2018
  Locations:          New York Presbyterian - Brooklyn Methodist Hospital, Brooklyn, New York, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03642080
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 49:
  NCT Number:          NCT03903640
  Title:            Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Melanoma With Brain Metastasis
  Interventions:        Device: Optune|Biological: Nivolumab|Biological: Ipilimumab
  Outcome Measures:       Intracranial progression-free survival|Overall survival|Best intracranial response rate|Best extracranial response rate|Extracranial progression-free survival|Safety of the treatment regimen as measured by number of treatment-related grade 3 or greater adverse events and discontinuations due to treatment related adverse events.
  Sponsor/Collaborators:    Washington University School of Medicine|NovoCure Ltd.
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 2
  Enrollment:          23
  Funded Bys:          Other|Industry
  Study Type:          Interventional
  Study Designs:        Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          201903162
  Start Date:          July 1, 2019
  Primary Completion Date:   January 31, 2024
  Completion Date:       July 31, 2027
  First Posted:         April 4, 2019
  Results First Posted:
  Last Update Posted:      August 11, 2020
  Locations:          Washington University School of Medicine, Saint Louis, Missouri, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03903640
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 50:
  NCT Number:          NCT03203525
  Title:            Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
  Acronym:
  Status:            Recruiting
  Study Results:        No Results Available
  Conditions:          Advanced Malignant Neoplasm|Colorectal Carcinoma Metastatic in the Liver|Metastatic Malignant Neoplasm in the Liver|Refractory Malignant Neoplasm
  Interventions:        Biological: Bevacizumab|Drug: Fluorouracil|Drug: Leucovorin|Drug: Oxaliplatin|Drug: Pegylated Liposomal Doxorubicin Hydrochloride|Drug: Temsirolimus|Procedure: Tumor Treating Fields Therapy
  Outcome Measures:       Incidence of adverse events|Response|Biomarker analysis
  Sponsor/Collaborators:    M.D. Anderson Cancer Center|National Cancer Institute (NCI)
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 1
  Enrollment:          52
  Funded Bys:          Other|NIH
  Study Type:          Interventional
  Study Designs:        Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          2014-0357|NCI-2018-01597|P30CA016672
  Start Date:          June 23, 2020
  Primary Completion Date:   December 31, 2021
  Completion Date:       December 31, 2021
  First Posted:         June 29, 2017
  Results First Posted:
  Last Update Posted:      August 12, 2020
  Locations:          M D Anderson Cancer Center, Houston, Texas, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT03203525
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 51:
  NCT Number:          NCT01756729
  Title:            Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
  Acronym:
  Status:            Terminated
  Study Results:        No Results Available
  Conditions:          Recurrent Glioblastoma Multiforme
  Interventions:        Device: NovoTTF-100A
  Outcome Measures:       Overall Survival|Change in neuro-cognitive function from baseline based on MMSE|Genetic profiling of tumors and correlation with response to NovoTTF-100A treatment|Adverse events severity and frequency
  Sponsor/Collaborators:    NovoCure Ltd.
  Gender:            All
  Age:             22 Years and older   (Adult, Older Adult)
  Phases:            Phase 4
  Enrollment:          13
  Funded Bys:          Industry
  Study Type:          Interventional
  Study Designs:        Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          EF-19
  Start Date:          December 2012
  Primary Completion Date:   January 2018
  Completion Date:       January 2018
  First Posted:         December 27, 2012
  Results First Posted:
  Last Update Posted:      March 2, 2016
  Locations:          University of Alabama at Birmingham, Birmingham, Alabama, United States|Barrow Neurology Clinics, Phoenix, Arizona, United States|University of California San Diego Moores Cancer Center, La Jolla, California, United States|Keck Medical Center of USC, Los Angeles, California, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Washington University School of Medicine, Division of Oncology, St. Louis, Missouri, United States|The Long Island Brain Tumor Center, Lake Success, New York, United States|Geisinger Health System, Danville, Pennsylvania, United States|Baylor Research Institute, Dallas, Texas, United States
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT01756729
-<WRAP center round download 98%>
+<WRAP center box 98%>
 Study 52:
  NCT Number:          NCT02903069
  Title:            Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
  Acronym:
  Status:            Active, not recruiting
  Study Results:        No Results Available
  Conditions:          Glioblastoma|Malignant Glioma
  Interventions:        Drug: MRZ|Drug: TMZ|Radiation: RT|Device: Optune
  Outcome Measures:       Determine MRZ maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) for both concomitant treatment (MRZ + TMZ + RT) and adjuvant treatment (MRZ + TMZ)|To assess adverse events during the adjuvant treatment|To confirm the MRZ RP2D for concomitant and adjuvant treatment in an expanded group of patients|Assess adverse events during concomitant and adjuvant treatment|Evaluate the activity (overall survival [OS]) of MRZ + TMZ + RT|Evaluate the activity (progression-free survival [PFS]) of MRZ + TMZ + RT|MRZ pharmacokinetics - Maximum Serum Concentration (Cmax)|MRZ pharmacokinetics - Elimination Half-Life (t1/2)|MRZ pharmacokinetics - Area Under the Blood Concentration-Time Curve (AUC0-t, AUC0-inf)|MRZ pharmacokinetics - Clearance (CL)|MRZ pharmacokinetics - Volume of Distribution (Vd)|TMZ serum concentration|Assess neurological coordination using the Scale for the Assessment and Rating for Ataxia (SARA)|Evaluate the activity (overall survival [OS]) of MRZ + TMZ + Optune|Evaluate the activity (progression-free survival [PFS]) of MRZ + TMZ + Optune
  Sponsor/Collaborators:    Celgene|Triphase
  Gender:            All
  Age:             18 Years and older   (Adult, Older Adult)
  Phases:            Phase 1
  Enrollment:          66
  Funded Bys:          Industry|Other
  Study Type:          Interventional
  Study Designs:        Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:          MRZ-112
  Start Date:          August 17, 2016
  Primary Completion Date:   February 26, 2021
  Completion Date:       February 26, 2021
  First Posted:         September 16, 2016
  Results First Posted:
  Last Update Posted:      March 9, 2021
  Locations:          University of California San Diego Medical Center, La Jolla, California, United States|UC Irvine, Orange, California, United States|John Wayne Cancer Center Outpatient Clinic, Santa Monica, California, United States|Northwestern Center For Clinical Research, Chicago, Illinois, United States|Duke Cancer Center, Durham, North Carolina, United States|Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|University of Zurich Hospital, Zurich, Switzerland
  Study Documents:
 </WRAP>
 URL:             https://ClinicalTrials.gov/show/NCT02903069

TTFields科研社区

用户工具

站点工具

差别

页面工具